… the development of NAFLD [9]. The present review elaborately discusses the epigenetic
mechanisms involved in NAFLD/NASH and possible therapeutic targets and therapies aiming at …

… for NASH/NAFLD. This review presents the agents currently used in managing NASH/NAFLD
and their pharmacologic targets. It also provides an overview of NAFLD agents currently …

… , and gut microbiome, with regard to therapy for NASH. In particular, we focus the … therapeutic
targets for NASH. We highlight these targets aiming to optimize the future for NASH therapy…

… NAFLD and NASH. Liver inflammation and cellular death, with or without fibrosis account for
the progression of NAFLD to NASH… important targets for the therapy of NAFLD and NASH. In …

… valuable in establishing potential targets of therapy and proposing … (NAFLD). The hepatokine
fibroblast growth factor (FGF)21, discussed further later in this article, as a therapy for NASH…

… in pre-clinical models of NASH [25]. It has been implicated in the pathogenesis of NAFLD/NASH
and has been a target for pharmacotherapy in the treatment of NASH [25]. Elafibranor, a …

… In our contribution, we review the most recent pharmacological target therapies, the role
of bariatric surgery, and the impact of liver transplantation on the NAFLD outcome. …

… of therapeutic agents to treat this epidemic; we anticipate the first FDA approval of a drug to
treat NASH … The pipeline for NASH therapeutics is rich and is the focus of this special issue of …

… target bile … for NAFLD is still an active and highly-needed area of ongoing investigation.
This study suggests that in the future, patients with NAFLD will likely require combination therapy …

… drugs specifically to treat NAFL/NASH, growing progress is being … therapeutic targets. In
this review, we discussed recent developments in etiology and prospective therapeutic targets, …